Evidence map›Paper›PMID 27348411›Full record

ArticleNature immunology2016

Hydrophobic CDR3 residues promote the development of self-reactive T cells.

Brian D Stadinski, Karthik Shekhar, Iria Gómez-Touriño, Jonathan Jung, Katsuhiro Sasaki, Andrew K Sewell, Mark Peakman, Arup K Chakraborty, Eric S Huseby

Open access · greenAbstract read
In one paragraph

Article in Nature immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 179 citations in OpenAlex.

  1. Trial
  2. Gliadin-specific CD4Science advances · 2026
    Article
  3. Review
  4. Article
  5. T Cell Thoughts.Immunological reviews · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Aberrant immune regulation and enrichment of stem-like CD8bioRxiv : the preprint server for biology · 2026
    Article
  13. Article
  14. Article
  15. Divergent T Cell Phenotypes Define Pediatric Crohn's Disease and Ulcerative Colitis.medRxiv : the preprint server for health sciences · 2025
    Article
  16. Article
  17. Preselection CD4bioRxiv : the preprint server for biology · 2025
    Article
  18. Article
  19. Article
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Brian D StadinskiDepartment of Pathology, University of Massachusetts Medical School Worcester, Massachusetts, USA.
Karthik ShekharBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Iria Gómez-TouriñoDepartment of Immunobiology, King's College London, London, UK.
Jonathan JungDepartment of Pathology, University of Massachusetts Medical School Worcester, Massachusetts, USA.
Katsuhiro SasakiDepartment of Pathology, University of Massachusetts Medical School Worcester, Massachusetts, USA.
Andrew K SewellDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
Mark PeakmanDepartment of Immunobiology, King's College London, London, UK.
Arup K ChakrabortyRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Eric S HusebyDepartment of Pathology, University of Massachusetts Medical School Worcester, Massachusetts, USA.
University of Massachusetts Chan Medical School · USKing's College London · GBBroad Institute · USCardiff University · GBRagon Institute of MGH, MIT and Harvard · US

Funding

PILOT AND FEASIBILITY PROGRAMP30DK032520 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CZECH, MICHAEL P · 1986 to 2010
$14.6M
T cell and transgenic core U19AI109858 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HUSEBY, ERIC S · 2014 to 2018
$11.9M
TRAINING IN IMMUNOLOGY (COMPETITIVE RENEWAL OF AI07439)T32AI007349 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI STERN, LAWRENCE J. · 1989 to 2024
$4.5M
Origin and Control of Self-Reactive TCRsR01DK095077 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HUSEBY, ERIC S · 2012 to 2016
$1.8M
NIAID NIH HHS T32 AI007349NIAID NIH HHS U19 AI109858NIDDK NIH HHS P30 DK032520NIDDK NIH HHS R01 DK095077
6 · The paper itself

Abstract

Studies of individual T cell antigen receptors (TCRs) have shed some light on structural features that underlie self-reactivity. However, the general rules that can be used to predict whether TCRs are self-reactive have not been fully elucidated. Here we found that the interfacial hydrophobicity of amino acids at positions 6 and 7 of the complementarity-determining region CDR3β robustly promoted the development of self-reactive TCRs. This property was found irrespective of the member of the β-chain variable region (Vβ) family present in the TCR or the length of the CDR3β. An index based on these findings distinguished Vβ2(+), Vβ6(+) and Vβ8.2(+) regulatory T cells from conventional T cells and also distinguished CD4(+) T cells selected by the major histocompatibility complex (MHC) class II molecule I-A(g7) (associated with the development of type 1 diabetes in NOD mice) from those selected by a non-autoimmunity-promoting MHC class II molecule I-A(b). Our results provide a means for distinguishing normal T cell repertoires versus autoimmunity-prone T cell repertoires.

Indexed as

AutoimmunityAnimalsAutoantigensCell DifferentiationCentral ToleranceComplementarity Determining RegionsDiabetes Mellitus, Type 1FemaleHigh-Throughput Nucleotide SequencingHistocompatibility Antigens Class IIHumansHydrophobic and Hydrophilic InteractionsMaleMiceMice, Inbred C57BLMice, Inbred NODAutoantigensComplementarity Determining RegionsHistocompatibility Antigens Class III-A(b) antigen, mouseI-A g7 antigen

Identifiers

PMID27348411
PMCPMC4955740
OpenAlexW2467278060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.